Evidence-based innovative treatment
targeting the cause of neurogenic dysphagia.
targeting the cause of neurogenic dysphagia.
Location: United States, New Hampshire, Manchester
Phone: 820 4525
Total raised: $113.39M
Founded date: 2007
Investors 3
| Date | Name | Website |
| - | Innvotec | innvotec.c... |
| - | Ranworth C... | ranworthca... |
| - | Inventages | inventages... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 05.09.2024 | Series D | $42M | - |
| 04.03.2024 | Series D | $42M | - |
| 22.05.2013 | Series B | $17M | - |
| 04.10.2011 | Series B | $9.31M | - |
| 11.09.2010 | - | $3.08M | - |
Mentions in press and media 16
| Date | Title | Description |
| 18.07.2026 | EQT Bolsters Global Footprint with Strategic Investments Across UK and Asia | EQT, a global investment powerhouse, is dynamically expanding its reach. The firm secured a €25 million commitment from the British Business Bank, boosting UK life sciences. Concurrently, EQT raised its tender offer for Kakaku.com in Japan ... |
| 17.07.2026 | British Business Bank backs EQT Life Sciences with €25M commitment | EQT Life Sciences’ EQT Health Economics 3 Fund (EQT HE3), a multi-stage life sciences and medtech-dedicated fund has received €25 million from the British Business Bank. EQT Life Sciences backs companies focused on the development of therap... |
| 05.09.2024 | Phagenesis Appoints Chad Hoskins as Chief Executive Officer Following Recent Close of $42M Series D Financing | Accomplished leader brings strong track record of commercial expansion in the US Company is focused on accelerating uptake of Phagenyx® to treat more patients in the US and Europe Phagenyx® is a first-of-its-kind therapy using neurostimulat... |
| 10.03.2024 | Phagenesis: A Game-Changer in Swallowing Dysfunction Treatment | Manchester-based company Phagenesis has secured a hefty $42M in Series D financing to further develop its innovative neurostimulation system for treating swallowing dysfunction. Led by EQT Life Sciences and Sectoral Asset Management, with n... |
| 04.03.2024 | Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management | MANCHESTER, England, March 4, 2024 /PRNewswire/ -- Phagenesis, a pioneering UK company which has developed a revolutionary neurostimulation system to treat swallowing dysfunction, has closed a $42M Series D financing all equity investment r... |
| 04.03.2024 | Exclusive: Medtech Phagenesis nets $42M Series D | Swallowing dysfunction treatment developer Phagenesis gobbled up $42 million in Series D financing, CEO Reinhard Krickl tells Axios exclusively. Why it matters: Swallowing difficulties or dysphagia result from brain injuries like stroke and... |
| 04.03.2024 | Phagenesis Closes $42M Series D Financing | Phagenesis, a Manchester, UK-based company which has developed a neurostimulation system to treat swallowing dysfunction, has closed a $42M Series D financing. The round was led by EQT Life Sciences and Sectoral Asset Management with partic... |
| 04.03.2024 | EQT Life Sciences and Sectoral lead $42M investment in medtech Phagenesis | Medtech company Phagenesis, which has developed a revolutionary neurostimulation system to treat swallowing dysfunction, has closed a $42 million Series D financing all-equity investment round. The Phagenyx® neurostimulation system targets ... |
| 22.05.2013 | Phagenesis Extends Series B Financing to $17M | Phagenesis, a Manchester, UK-based developer of solutions for the treatment of dysphagia, has expanded its Series B financing to $17m. The company had raised €7m in Series B (read here) and £2m in a Series A financing in 2010 (read here). T... |
| 22.05.2013 | Phagenesis Expands Series B to $17M | MANCHESTER, ENGLAND, Leading company in the treatment of dysphagia, has expanded its Series B financing to $17M. >> Click here for more funding data on Phagenesis >> To export Phagenesis funding data to PDF and Excel, click ... |
Show more